GovChime
Notice ID: e997eaeb66554202b348e3fc183d50d9Presolicitation

Boston Biosciences Protein EBov and CARS-CoV2 synthesis

Archived on August 29, 2020. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
10:00 AM UTC−04:00
Posted
August 5, 2020
Notice type
Presolicitation
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Bethesda, MD, 20892
Last updated
Apr 29, 2026

Identifiers

Solicitation number
NOI-NIAID-2032622
Notice ID
e997eaeb66554202b348e3fc183d50d9

Description

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Boston Bioscience, Inc Royal Oak, MI 48073 for EBOV protein, 15 aa in length, C-terminal acid form, Free N-terminal form, EBOV protein, 15 aa in length, C-terminal acid form, Biotin-Ahx N-terminal form, SARS-CoV2 spike protein, 15 aa in length, C-terminal acid form, Free N-terminal form, and SARS-CoV2 spike protein, 15 aa in length, C-terminal acid form, Biotin-Ahx N-terminal form for assay development and immune analysis of vaccine recipient samples. The Vaccine Research Center (VRC) is performing critical work in pandemic response to SARS-CoV-2 infection (i.e., COVID-19). These efforts include analyzing SARS-CoV-2 specific immune responses following infection and vaccine induced immune response. This work is needed critically and urgently to support the pandemic response efforts of the VRC to SARS-CoV-2. This project seeks to apply a variety of different assay techniques to identify antigen-specific epitopes in serum following infection by or immunization against viral pathogens, using hundreds of customized peptides. Development of these assays will directly support pre-clinical assessment of novel coronavirus vaccines and support the effort in characterizing the Moderna coronavirus vaccine candidate. Boston Biosciences protocols are approved and in place to optimally synthesize and purify the difficult peptides. In addition, following their industry standard cleanup of impurities, Boston Biosciences has the additional proprietary cleanup of the peptides that is required and approved for our clinical trials. No substitutions are allowed on this project. The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2032622) to Skye Duffner at skye.duffner@nih.gov, by 10:00 am eastern standard time, August 14, 2020. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:NOI-NIAID-2032622
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentAug 5, 2020

    Boston Biosciences Protein EBov and CARS-CoV2 synthesis

    Notice e997eaeb66554202b348e3fc183d50d9 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

NOI-NIAID-2032622

Archive Date

Aug 29, 2020

Office Address

BETHESDA, MD, 20892